Literature DB >> 25502369

A high cell density transient transfection system for therapeutic protein expression based on a CHO GS-knockout cell line: process development and product quality assessment.

Yashas Rajendra1, Maria D Hougland, Riazul Alam, Teresa A Morehead, Gavin C Barnard.   

Abstract

Transient gene expression (TGE) is a rapid method for the production of recombinant proteins in mammalian cells. While the volumetric productivity of TGE has improved significantly over the past decade, most methods involve extensive cell line engineering and plasmid vector optimization in addition to long fed batch cultures lasting up to 21 days. Our colleagues have recently reported the development of a CHO K1SV GS-KO host cell line. By creating a bi-allelic glutamine synthetase knock out of the original CHOK1SV host cell line, they were able to improve the efficiency of generating high producing stable CHO lines for drug product manufacturing. We developed a TGE method using the same CHO K1SV GS-KO host cell line without any further cell line engineering. We also refrained from performing plasmid vector engineering. Our objective was to setup a TGE process to mimic protein quality attributes obtained from stable CHO cell line. Polyethyleneimine (PEI)-mediated transfections were performed at high cell density (4 × 10(6) cells/mL) followed by immediate growth arrest at 32 °C for 7 days. Optimizing DNA and PEI concentrations proved to be important. Interestingly, found the direct transfection method (where DNA and PEI were added sequentially) to be superior to the more common indirect method (where DNA and PEI are first pre-complexed). Moreover, the addition of a single feed solution and a polar solvent (N,N dimethylacetamide) significantly increased product titers. The scalability of process from 2 mL to 2 L was demonstrated using multiple proteins and multiple expression volumes. Using this simple, short, 7-day TGE process, we were able to successfully produce 54 unique proteins in a fraction of the time that would have been required to produce the respective stable CHO cell lines. The list of 54 unique proteins includes mAbs, bispecific antibodies, and Fc-fusion proteins. Antibody titers of up to 350 mg/L were achieved with the simple 7-day process. Titers were increased to 1 g/L by extending the culture to 16 days. We also present two case studies comparing product quality of material generated by transient HEK293, transient CHO K1SV GS-KO, and stable CHO K1SV KO pool. Protein from transient CHO was more representative of stable CHO protein compared to protein produced from HEK293.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  GS CHO; mammalian cells; polyethyleneimine; transfection; transient gene expression

Mesh:

Substances:

Year:  2015        PMID: 25502369     DOI: 10.1002/bit.25514

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  The transient expression of CHIKV VLP in large stirred tank bioreactors.

Authors:  Peifeng Chen; Jacob Demirji; Vera B Ivleva; Joe Horwitz; Richard Schwartz; Frank Arnold
Journal:  Cytotechnology       Date:  2019-09-27       Impact factor: 2.058

Review 2.  Progress of cationic gene delivery reagents for non-viral vector.

Authors:  Kai Ma; Chun-Liu Mi; Xiang-Xiang Cao; Tian-Yun Wang
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-04       Impact factor: 4.813

3.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

4.  A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.

Authors:  Hiroko Ishii; Maram H Zahra; Atushi Takayanagi; Masaharu Seno
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

5.  RNase H-dependent PCR enables highly specific amplification of antibody variable domains from single B-cells.

Authors:  John Crissman; Yuhao Lin; Kevin Separa; Madeleine Duquette; Michael Cohen; Candyd Velasquez; Thomas Cujec
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

6.  Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales.

Authors:  Sara Rodriguez-Conde; Sophie Inman; Viv Lindo; Leanne Amery; Alison Tang; Uche Okorji-Obike; Wenjuan Du; Berend-Jan Bosch; Paul J Wichgers Schreur; Jeroen Kortekaas; Isabel Sola; Luis Enjuanes; Laura Kerry; Katharina Mahal; Martyn Hulley; Olalekan Daramola
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.